Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

101. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy Full Text available with Trip Pro

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications Including stroke and sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated with AF in this population (...) , including the evidence in support of higher stroke risk in patients with HCM with AF compared with the general AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.

2017 Arrhythmia & electrophysiology review

102. Edoxaban (Roteas) - anticoagulant

Edoxaban (Roteas) - anticoagulant 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 February 2017 EMA/158410/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Roteas International non-proprietary name: edoxaban Procedure No. EMEA/H/C/004339/0000 Note Assessment report as adopted by the CHMP with all (...) COPD Chronic obstructive pulmonary disease eCTD Electronic Common Technical Document DOAC Direct oral anticoagulants DVT Deep vein thrombosis EC European Commission EEA European Economic Area EMA European Medicines Agency EPAR European Public Assessment Report EU European Union eg exampli gratia (for example) FXa Factor Xa ie id est (that is) INR International normalised ratio LMWH Low molecular weight heparin MA Marketing authorisation MAA Marketing authorisation application MAH Marketing

2017 European Medicines Agency - EPARs

103. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study Full Text available with Trip Pro

Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study Direct oral anticoagulant (DOAC) agents increase the risk of gastrointestinal (GI) bleeding. We investigated which DOAC had the most favorable GI safety profile and compared differences among these drugs in age-related risk of GI bleeding.We conducted a retrospective, propensity-matched study using administrative claims data from the OptumLabs Data Warehouse of privately insured individuals and Medicare

2017 EvidenceUpdates

104. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism (Abstract)

External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism One of the main determinants of establishing the optimal treatment duration of patients with venous thromboembolism (VTE) is the risk of major bleeding during long-term anticoagulant therapy. The 6-variable VTE-BLEED score was recently developed to enable estimation of this bleeding risk. This study aimed at externally validating VTE-BLEED. This was a post-hoc (...) study of the randomised, double-blind, double-dummy, Hokusai-VTE study that compared edoxaban versus warfarin for treatment of VTE. VTE-BLEED was calculated in all 8,240 study patients. The numbers of adjudicated major bleeding events during 'stable anticoagulation', i. e. occurring after day 30, in patients with low (total score <2 points) and high risk of bleeding (total score ≥2 points) were compared for the overall study population, patients randomised to edoxaban or warfarin, and for important

2017 EvidenceUpdates

105. Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice Full Text available with Trip Pro

Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice Following the implementation of citrate anticoagulation for continuous renal replacement therapy, we evaluate its first year of use and compare it to the previously used heparin, to assess whether our patients benefit from the recently reported advantages of citrate. We (...) retrospectively analysed 2 years of data to compare the safety and efficacy of citrate versus heparin. The results have shown that 43 patients received continuous renal replacement therapy with heparin, 37 patients with citrate. We found no significant difference in metabolic control of pH, urea and creatinine after 72 h. Filters anticoagulated with citrate had significantly longer median lifespan (33 h vs 17 h; p = 0.001), shorter downtime (0 h vs 5 h; p = 0.015) and less filter sets per patient day (0.37 vs

2017 Journal of the Intensive Care Society

106. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Full Text available with Trip Pro

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant.Design Propensity weighted (inverse probability of treatment weighted) nationwide (...) cohort study.Setting Individual linked data from three nationwide registries in Denmark.Participants Patients with non-valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non-vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four treatment

2017 BMJ

107. Management of Isolated Calf DVTs with Anticoagulation

Management of Isolated Calf DVTs with Anticoagulation Emergency Medicine > Journal Club > Archive > August 2016 Toggle navigation August 2016 Management of Isolated Calf DVTs with Anticoagulation Vignette Mr. M is a 53-year-old patient with a history of high blood pressure and high cholesterol who flew back to St. Louis from Shanghai five days ago. Two days after getting back he noted pain and swelling in his left calf, which he thought was due to a muscle strain while getting off (...) of years that spoke about the controversy surrounding this dogma. You send Mr. P home and recommend repeat dopplers in 5-7 days, but later decide to search the literature in order to make your own evidence-based decision... PICO Question Population: Adult patients with isolated calf DVT distal to the popliteal veins Intervention: Therapeutic anticoagulation (heparin, low molecular weight heparin, factor Xa inhibitor, direct thrombin inhibitor, or vitamin K antagonist) Comparison: No anticoagulation

2017 Washington University Emergency Medicine Journal Club

108. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Van Brabandt H, San Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Van Brabandt H, San (...) Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C. Anticoagulants in non-valvular atrial fibrillation. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports. 2017 Authors' conclusions • International practice guidelines recommend prescribing anticoagulants to patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score ≥ 2 (for men) and score ≥ 3 (for women). For a CHA2DS2-VASc score = 0 they are best not prescribed. In patients

2017 Health Technology Assessment (HTA) Database.

109. Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines

Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines (...) Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: January 31, 2017 Project Number: RD0035-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the comparative effectiveness and safety of idarucizumab versus standard supportive care for reversing the anticoagulation state in adults treated with dabigatran

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

110. Head Injury and patients on Anticoagulation/Antiplatelet Therapies

Head Injury and patients on Anticoagulation/Antiplatelet Therapies Head Injury and patients on anticoagulant or antiplatelet therapy 1 Head Injury and Patients on Anticoagulant/Antiplatelet Therapies Citation Garrubba M. 2017. Head Injury and Patients on Anticoagulant/Antiplatelet Therapies: A Scoping Review. Centre for Clinical Effectiveness, Monash Innovation and Quality, Monash Health, Melbourne, Australia. Executive Summary Background The Centre for Clinical Effectiveness was requested (...) to review the evidence for managing patients who present with mild trauma to the head and are known to be on oral anticoagulant, antiplatelet therapy. Objective The objectives of this scoping review were to determine: A. How anticoagulants or antiplatelet agents should be managed for patients with minor head trauma? B. What is the optimal timing and frequency of Computed Tomography (CT) brain scans in the period following the minor head trauma (e.g. fall) to determine if intracranial bleeding has

2017 Monash Health Evidence Reviews

111. Qualitative study?other: Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes

Qualitative study?other: Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes Article Text Adult

2017 Evidence-Based Nursing

112. Qualitative study?other: Individualised assessment is required to establish the most appropriate anticoagulation option for patients

Qualitative study?other: Individualised assessment is required to establish the most appropriate anticoagulation option for patients Individualised assessment is required to establish the most appropriate anticoagulation option for patients | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Individualised assessment is required to establish the most appropriate anticoagulation option for patients Article Text Adult nursing Qualitative study

2017 Evidence-Based Nursing

113. Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy

Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Article Text Community and primary care nursing Systematic

2017 Evidence-Based Nursing

115. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

116. Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

2017 DynaMed Plus